Energy loss via urine and faeces - a combustive analysis in diabetic rats and the impact of antidiabetic treatment on body weight

Diabetes, Obesity and Metabolism

Volumn 15, Issue 4, 2013, Pages 324-334

  Elvert, R ^a   Wille, A ^a   Wandschneider, J ^a   Werner, U ^a   Glombik, H ^a   Herling, A W ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Diabetes; Energy balance; Energy excretion; Faeces; Insulin glargine; Lixisenatide; SGLT2 inhibition; Urine

Indexed keywords

2 [2 (4 METHOXYBENZYL)THIOPHENYL] BETA DEXTRO GLUCOPYRANOSIDE; ANTIDIABETIC AGENT; AVE 2268; GLUCOSE; INSULIN GLARGINE; LIXISENATIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; ENERGY BALANCE; ENERGY EXPENDITURE; FECES ANALYSIS; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSURIA; GLYCEMIC CONTROL; MALE; NONHUMAN; RAT; URINALYSIS; URINARY EXCRETION; WEIGHT CHANGE; WEIGHT GAIN; ZUCKER DIABETIC FATTY RAT;

EID: 84874344116     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12030     Document Type: Article

References (47)

1. Emery AG, Benedict FG. The heat of combustion of compounds of physiological importance. Am J Physiol 1911; 28: 301-307.
2. Miles CW, Webb P, Bodwell CE. Metabolizable energy of human mixed diets. Hum Nutr Appl Nutr 1986; 40: 333-346.
3. Joffe D, Yanagisawa RT. Metabolic syndrome and type 2 diabetes: can we stop the weight gain with diabetes? Med Clin North Am 2007; 91: 1107-1123.
4. Levetan C. Oral antidiabetic agents in type 2 diabetes. Curr Med Res Opin 2007; 23: 945-952.
5. Nichols GA, Gomez-Caminero A. Weight changes following the initiation of new anti-hyperglycaemic therapies. Diabetes Obes Metab 2007; 9: 96-102.
6. Chiasson JL, Josse RG, Hunt JA et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994; 121: 928-935.
7. Albu J, Raja-Khan N. The management of the obese diabetic patient. Prim Care 2003; 30: 465-491.
8. Kelley D, Bidot P, Freedman Z et al. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. Diabetes Care 1998; 21: 2056-2061.
9. Shah NK, Deeb WE, Choksi R, Epstein BJ. Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2012; 32: 80-94.
10. Devineni D, Morrow L, Hompesch M et al. Canagliflozin improves glycaemic control over 28days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012; 14: 539-545.
11. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 2012; 8: 495-502.
12. Jabbour SA, Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract 2008; 62: 1279-1284.
13. Combettes M, Kargar C. Newly approved and promising antidiabetic agents. Therapie 2007; 62: 293-310.
14. Krentz AJ, Bailey CJ. Oral antidiabetic agents. Drugs 2005; 65: 385-411.
15. Carver C. Insulin treatment and the problem of weight gain in type 2 diabetes. Diabetes Educ 2006; 32: 910-917.
16. Barnett A, Allsworth J, Jameson K, Mann R. A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. Curr Med Res Opin 2007; 23: 1493-1507.
17. Werner U, Haschke G, Herling AW, Kramer W. Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept 2010; 164: 58-64.
18. Liu SC, Tu YK, Chien MN, Chien KL. Effect of antidiabetic agents added to metformin on glycemic control, hypoglycemia and weight change in patients with type 2 diabetes: a network meta-analysis. Diabetes Obes Metab 2012; 14: 810-820.
19. Larsen P. Mechanisms behind GLP-1 induced weight loss. Br J Diabetes Vasc Dis 2008; 8(Suppl 2): S34-41.
20. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analysis of randomised controlled trials. BMJ 2012; 344: 1-11.
21. Jacob AN, Salinas K, Adams-Huet B, Raskin P. Weight gain in type 2 diabetes mellitus. Diabetes Obes Metab 2007; 9: 386-393.
22. Drozdz A, Weiner J. Some bioenergetic parameters of wild ruminants. Pol Ecol Stud 1975; 1: 85-101.
23. Bickel M, Brummerhop H, Frick W et al. Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. Arzneimittelforschung 2008; 58: 574-580.
24. Stammberger I, Bube A, Durchfeld-Meyer B, Donaubauer H, Troschau G. Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol 2002; 21: 171-179.
25. Meyer C, Elvert R, Scherag A et al. Power matters in closing the phenotyping gap. Naturwissenschaften 2007; 94: 401-406.
26. Raman A, Baum ST, Colman RJ, Kemnistz JW, Weindruch R, Schoeller DA. Metabolizable energy intake during long-term calorie restriction in rhesus monkeys. Exp Gerontol 2007; 42: 988-994.
27. Singh R, Martin BR, Hickey Y et al. Comparison of self-reported and measured metabolizable energy intake with total energy expenditure in overweight teens. Am J Clin Nutr 2009; 89: 1744-1750.
28. Ness-Abramof R, Apovian CM. Drug-induced weight gain. Drugs Today 2005; 41: 547-555.
29. DCCT Research Group. Weight gain associated with intensive therapy in the diabetes control and complications trial. Diabetes Care 1988; 11: 567-573.
30. Larger E. Weight gain and insulin treatment. Diabetes Metab 2005; 31: 4s51-4s56.
31. D'Arrigo T. A matter of balance. Insulin and weight gain. Diabetes Forecast 2007; 60: 16.
32. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes 2002; 26(Suppl 3): S18-24.
33. Heller S. Weight gain during insulin therapy in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2004; 65S: S23-27.
34. Carlson MG, Campbell PJ. Intensive insulin therapy and weight gain in IDDM. Diabetes 1993; 42: 1700-1707.
35. Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia 1999; 42: 406-412.
36. Wang F, Carabino JM, Vergara CM. Insulin glargine: a systematic review of a long-acting insulin analogue. Clin Ther 2003; 25: 1541-1577.
37. Chatterjee S, Tringham JR, Davies MJ. Insulin glargine and its place in the treatment of Types 1 and 2 diabetes mellitus. Expert Opin Pharmacother 2006; 7: 1357-1371.
38. Bush M. Intensive diabetes therapy and body weight: focus on insulin detemir. Endocrinol Metab Clin North Am 2007; 36: 33-44.
39. Torbay N, Bracco EF, Geliebter A, Stewart IM, Hashim SA. Insulin increases body fat despite control of food intake and physical activity. Am J Physiol 1985; 248: R120-124.
40. Saudek CD, Duckworth WC, Giobbie-Hurder A et al. Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus: a randomized clinical trial. Department of Veterans Affairs Implantable Insulin Pump Study Group. JAMA 1996; 276: 1322-1327.
41. +-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats. Life Sci 2005; 76: 2655-2668.
42. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
43. Katsuno K, Fujimori Y, Takemura Y et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 2006; 320: 323-330.
44. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650-657.
45. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409-1439.
46. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008; 60: 470-512.
47. Moore MC, Werner U, Smith MS, Rodewald TD, Cherrington AD. Effect of the glucagon-like peptide-1 receptor agonist AVE0010 on postprandial hepatic glucose metabolism in the conscious dog. Diabetologia 2007; 50: S242.